Harrow, Inc. (HROW) Q4 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Harrow, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.839 Good day and welcome to the HARO fourth quarter 2025 earnings conference call. 00:00:04.839 -- 00:00:07.944 At this time, all participants are in listen-only mode. 00:00:07.944 -- 00:00:11.489 After the speaker's presentation, there will be a question and answer session. 00:00:11.489 -- 00:00:13.312 Please note that this call may be recorded. 00:00:13.312 -- 00:00:17.699 I would now like to turn the call over to Mike Biega, Vice President, Investor Relations 00:00:17.699 -- 00:00:21.262 and Communications. Please go ahead. 00:00:22.458 -- 00:00:27.405 Good morning, and welcome to HARO's fourth quarter and full year 2025 earnings conference 00:00:27.405 -- 00:00:32.672 call. My name is Mike Biega, Vice President of Investor Relations and Communications, 00:00:32.672 -- 00:00:35.796 and I'm excited to be introducing today's call. 00:00:35.796 -- 00:00:39.841 The company's remarks may include forward-looking statements within the meaning of federal 00:00:39.841 -- 00:00:45.323 securities laws. Forward-looking statements are subject to numerous risks and uncertainties, 00:00:45.323 -- 00:00:49.549 many of which are beyond HARO's control, including risks and uncertainties described 00:00:49.549 -- 00:00:54.535 from time to time in its SEC filings, such as the risks and uncertainties related to 00:00:54.535 -- 00:00:59.662 the company's ability to make commercially available its FDA-approved products and compounded 00:00:59.662 -- 00:01:04.889 formulations and technologies and FDA approval of certain drug candidates in a timely 00:01:04.889 -- 00:01:09.875 manner or at all. For a list and description of those risks and uncertainties, please 00:01:09.875 -- 00:01:15.361 see the risk factors section of the company's most recent annual repo...